Clinical Trial Update: A Comparison of Subject-administered Romosozumab With Healthcare Provider-administered Romosozumab for Osteoporosis [Phase 3]

View source ↗

Summary

Phase 3 trial comparing self-administered vs healthcare provider-administered romosozumab in post-menopausal osteoporosis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Post-menopausal Osteoporosis

Drugs mentioned

• Romosozumab (romosozumab)

Snippet

Sponsor: Amgen | Conditions: Post-Menopausal Osteoporosis | Phase 3 | Status: COMPLETED | Results posted: 2020-04-10